- Home
- ST vs IBRX Comparison
ST vs IBRX Comparison
Compare ST & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ST
- IBRX
- Stock Information
- Founded
- ST 1916
- IBRX 2014
- Country
- ST United States
- IBRX United States
- Employees
- ST N/A
- IBRX N/A
- Industry
- ST Industrial Machinery/Components
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ST Industrials
- IBRX Health Care
- Exchange
- ST Nasdaq
- IBRX Nasdaq
- Market Cap
- ST 3.0B
- IBRX 2.4B
- IPO Year
- ST 2010
- IBRX N/A
- Fundamental
- Price
- ST $19.47
- IBRX $2.47
- Analyst Decision
- ST Buy
- IBRX Strong Buy
- Analyst Count
- ST 12
- IBRX 5
- Target Price
- ST $34.55
- IBRX $11.35
- AVG Volume (30 Days)
- ST 2.5M
- IBRX 8.0M
- Earning Date
- ST 04-28-2025
- IBRX 05-08-2025
- Dividend Yield
- ST 2.48%
- IBRX N/A
- EPS Growth
- ST N/A
- IBRX N/A
- EPS
- ST 0.85
- IBRX N/A
- Revenue
- ST $3,932,764,000.00
- IBRX $14,745,000.00
- Revenue This Year
- ST N/A
- IBRX $621.53
- Revenue Next Year
- ST $4.38
- IBRX $163.57
- P/E Ratio
- ST $22.91
- IBRX N/A
- Revenue Growth
- ST N/A
- IBRX 2270.58
- 52 Week Low
- ST $17.32
- IBRX $2.28
- 52 Week High
- ST $43.14
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- ST 34.63
- IBRX 41.67
- Support Level
- ST $18.87
- IBRX $2.35
- Resistance Level
- ST $20.25
- IBRX $3.04
- Average True Range (ATR)
- ST 1.63
- IBRX 0.28
- MACD
- ST -0.10
- IBRX -0.02
- Stochastic Oscillator
- ST 28.29
- IBRX 13.19
About ST Sensata Technologies Holding plc
Sensata Technologies is a global supplier of sensors for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.